REG - Cambridge Cognition - Result of General Meeting
RNS Number : 4653FCambridge Cognition Holdings PLC09 March 2020Cambridge Cognition Holdings Plc
("Cambridge Cognition" or the "Company")
Result of General Meeting
Cambridge Cognition Holdings plc, which develops and markets neuroscience technology to assess brain health, is pleased to announce that all of the Resolutions proposed at the General Meeting held at its offices today to approve the proposed Placing and Subscription of up to 7,000,000 New Ordinary Shares and other related matters were duly passed.
Full details of the Resolutions were set out in the Circular published by the Company on 19 February 2020. The Circular is available for inspection in electronic form on the Company's website, www.cambridgecognititon.com.
Total Voting Rights
Further to Admission, the Company's issued Ordinary Share capital will consist of 31,170,093 Ordinary Shares of 1 pence each, with voting rights. The Company does not hold any shares in Treasury.
Therefore the total number of voting rights is 31,170,093 and this figure may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Defined terms used in this announcement have the meanings ascribed to them in the circular to shareholders dated 19 February 2020 unless otherwise defined.
Enquiries
Cambridge Cognition Holdings PLC
Matthew Stork, Chief Executive Officer
Nick Walters, Chief Financial Officer
Tel: 01223 810 700
finnCap Ltd (NOMAD and Joint Broker)
Geoff Nash / Simon Hicks / Teddy Whiley
Alice Lane/Manasa Patil
Tel: 020 7220 0500
(Corporate Finance)
(ECM)
Dowgate Capital Limited (Joint Broker)
David Poutney / James Serjeant
Tel: 020 3903 7715
IFC Advisory Ltd (Financial PR and IR)
Tim Metcalfe / Graham Herring / Zach Cohen
Tel: 020 3934 6630
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDROMFLFSFVIIAIII
Recent news on Cambridge Cognition Holdings
See all newsREG - Cambridge Cognition - Preliminary Results, Trading Update & Board Change
AnnouncementREG - Cambridge Cognition - Notice of Results
AnnouncementREG - Cambridge Cognition - COG spin-out Monument Therapeutics accesses £1.5m
AnnouncementREG - Cambridge Cognition - Total Voting Rights and Block Listing Return
AnnouncementREG - Cambridge Cognition - Formation of new Scientific Advisory Board
Announcement